newsfilter
← Latest News
GlobeNewswire·

Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights

Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS) Completed a $4.0 million registered